Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 6/2005

01-06-2005 | Leading Article

Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies

Clinical and Radiological Characteristics and Pharmacological Treatment Options

Authors: Dr Éric Toussirot, Daniel Wendling

Published in: Drugs & Aging | Issue 6/2005

Login to get access

Abstract

Ankylosing spondylitis is the prototype of related diseases commonly called spondylarthropathies which include reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel diseases (enteropathic arthritis) and undifferentiated spondylarthropathies. Ankylosing spondylitis and spondylarthropathies are generally observed in young patients but can be observed later in life or in persons >50 years of age. All the spondylarthropathy subgroups are represented in the elderly with some features particular to this age group. Indeed, radiological aspects of ankylosing spondylitis may be difficult to interpret because of the radiological changes induced by aging. Late-onset peripheral spondylarthropathies are characterised by severe disease, marked elevation of laboratory parameters of inflammation, oligoarthritis involving the lower limbs and oedema of the extremities. Psoriatic arthritis is more severe in the elderly and is associated with worse outcomes than in young patients. The clinical presentation of undifferentiated spondylarthropathy is as varied in the elderly as in young and middle-aged adults. Reactive arthritis and enteropathic arthritis are observed in the elderly more rarely.
The effects of aging on drug metabolism and pharmacokinetics, together with the existence of co-morbidities and polypharmacy, are responsible for difficulties in the therapeutic management of late-onset ankylosing spondylitis or spondylarthropathies. Indeed, NSAIDs should be used with caution in older patients because of the high risk of serious gastrointestinal complications. Sulfasalazine and methotrexate have been used as disease-controlling drugs but did not prove very effective. Pamidronate and tumour necrosis factor (TNF)-α antagonists offer a therapeutic alternative but have not been specifically tested in the elderly. Pamidronate has been tested in young-onset ankylosing spondylitis and spondylarthropathies with conflicting results but can be used in older patients without risk of major adverse effects. TNFα antagonists have been adequately evaluated in ankylosing spondylitis and spondylarthropathies and are associated with dramatic improvement in clinical and biological parameters of disease activity. However, the safety profile of these agents in the elderly is not currently known and careful surveillance, in particular for the risk of infection such as tuberculosis, and/or exacerbation of chronic heart failure, is thus required when using these drugs in this age group.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Wollheim FA. Ankylosing spondylitis. In: Kelley WN, Harris ED, Ruddy S, editors. Textbook of rheumatology. Philadelphia (PA): Saunders 1993: 943–55
2.
Van Der Linden S, Van Der Heijde D. Ankylosing spondylitis: clinical features. Rheum Dis Clin North Am 1998; 24: 663–76PubMedCrossRef
3.
Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40: 1823–8PubMedCrossRef
4.
Calin A. Terminology, introduction, diagnostic criteria and overview. In: Calin A, Taurog JD, editors. The spondylarthritides. Oxford: Oxford University Press, 1998: 1–15
5.
Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. J Rheumatol 1999; 26: 2622–7PubMed
6.
Guillemin F, Saraux A, Guggenbuhl P, et al. Prévalence de la polyarthrite rhumatoïde et des spondylarthropathies en France en 2001. Rev Rhum [Ed Fr] 2002; 69: 1014CrossRef
7.
Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 766–71PubMedCrossRef
8.
Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002; 20Suppl. 28: S23–6PubMed
9.
Amor B, Santos RS, Nahal R, et al. Predictive factors for the longterm outcome of spondylarthropathies. J Rheumatol 1994; 21: 1883–7PubMed
10.
Braun J, Pincus T. Mortality, course of the disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20Suppl. 28: S16–22PubMed
11.
12.
Creemers MCW, Van Riel PCLM, Franssen MJAM. Second-line treatment in seronegative spondylarthropathies. Semin Arthritis Rheum 1994; 24: 71–81PubMedCrossRef
13.
Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998; 56: 225–40PubMedCrossRef
14.
Wendling, Toussirot E. Anti-TNFα therapy in ankylosing spondylitis. Exp Opin Pharmacother 2004; 5: 1497–507CrossRef
15.
Dubost JJ, Sauvezie B. Actualités des rhumatismes inflammatoires du sujet âgé. Rev Rhum 1992; 59 (6 bis): 38S–42S
16.
Amor B, Bouchet H, Delrieu F. Enquête nationale sur les arthrites réactionnelles de la Société Française de Rhumatologie. Rev Rhum 1983; 50: 733–43PubMed
17.
Carbone LD, Cooper C, Michet CJ, et al. Ankylosing spondylitis in Rochester, Minnesota 1935–1989: is the epidemiology changing? Arthritis Rheum 1992; 35: 1476–82PubMedCrossRef
18.
Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000; 12: 239–47PubMedCrossRef
19.
Dubost JJ, Ristori JM, Zmantar C, et al. Rhumatismes séronégatifs à début Tardif: fréquence et atypie des spondylarthropathies. Rev Rhum 1991; 58: 577–84PubMed
20.
Van der Linden SM, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8PubMedCrossRef
21.
Dubost JJ, Sauvezie B. Late onset peripheral spondylarthropathy. J Rheumatol 1989; 16: 1214–7PubMed
22.
Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthropathy: clinical and biological comparison with early onset patients. Ann Rheum Dis 1997; 56: 176–9PubMedCrossRef
23.
Olivieri I, Padula A, Pierro A, et al. Late onset seronegative spondylarthropathy. J Rheumatol 1995; 22: 899–903PubMed
24.
Kay LJ, Walker DJ. Late onset spondylarthropathy: comparison with early onset patient [letter]. Ann Rheum Dis 1997; 57: 572CrossRef
25.
Amor B, Dougados M, Mijiyama M. Critères de classification des spondylarthropathies. Rev Rhum 1990; 57: 85–9PubMed
26.
Garrett S, Jenkinson T, Whitelock H, et al. A new approach to defining disease status in AS: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J Rheumatol 1994; 21: 2286–91PubMed
27.
Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index (BASFI). J Rheumatol 1994; 21: 2281–5PubMed
28.
Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset and disease expression. J Rheumatol 2001; 28: 2283–8PubMed
29.
Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol 1996; 35: 1289–91PubMedCrossRef
30.
Punzi L, Pianon M, Rossini P, et al. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999; 58: 226–9PubMedCrossRef
31.
Dougados M, Van Der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group: the European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218–27PubMedCrossRef
32.
McCarty DJ, O’Duffy JD, Pearson L, et al. Remitting synovitis seronegative symmetric synovitis with pitting edema (RS3PE) syndrome. JAMA 1985; 254: 2763–7PubMedCrossRef
33.
Cantini F, Salvanari C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: a prospective follow-up and magnetic resonance imaging study. Ann Rheum Dis 1999; 58: 230–6PubMedCrossRef
34.
Ponce A, Sanmarti R, Orellana C, et al. Spondylarthropathy presenting as polymyalgia rheumatica-like syndrome. Clin Rheumatol 1997; 16: 614–6PubMedCrossRef
35.
Olivieri I, Salvanari C, Cantini F, et al. Ankylosing spondylitis and undifferentiated spondylarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 2001; 13: 280–4PubMedCrossRef
36.
Koeger AC, Karmochkine M, Chaïbi P. RS3PE syndrome associated with advanced ankylosing spondylitis. J Rheumatol 1995; 22(2): 375–6PubMed
37.
Anderson JJ, Baron G, Van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876–86PubMedCrossRef
38.
Wanders A, Van Der Heijde D, Landewé R, et al. Inhibition of radiographic progression in ankylosing spondylitis by continuous use of NSAIDs. Arthritis Rheum 2003; 48Suppl. 1: S233
39.
Buffum M, Buffum JC. Non steroidal antiinflammatory drugs in the elderly. Pain Manag Nurs 2000; 1: 40–50PubMedCrossRef
40.
Greenwald DA. Aging, the gastrointestinal tract, and the risk of acid related disease. Am J Med 2004; 117(5A): 8S–13SPubMed
41.
Nikolaus T, Zeyfang A. Pharmacological treatments for persistent non-malignant pain in older persons. Drugs Aging 2004; 21: 19–41PubMedCrossRef
42.
Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303–9PubMedCrossRef
43.
44.
Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20: 23–57PubMedCrossRef
45.
Beyth R, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999; 14: 231–9PubMedCrossRef
46.
Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999; 56: 18–24PubMed
47.
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 294: 1247–55CrossRef
48.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000; 343: 1520–8PubMedCrossRef
49.
Dougados M, Behier J, Jolchine I, et al. Efficacy of celecoxib, a COX-2 specific inhibitor in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against conventional nonsteroidal anti-inflammatory drug. Arthritis Rheum 2001; 44: 180–5PubMedCrossRef
50.
Emery P, Baraf HS, Schiff M, et al. Etoricoxib, a COX-2 selective inhibitor in ankylosing spondylitis patients with poor response to non steroidal anti-inflammatory drugs [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 99
51.
52.
Marzo-Ortega H, Emery P, McGonagle D. The concept of disease modification in spondylarthropathy. J Rheumatol 2002; 29: 959–65
53.
Dougados M, Van Der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618–27PubMedCrossRef
54.
Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1999; 42: 2325–9PubMedCrossRef
55.
Bosi-Ferraz M, Tugwell P, Goldsmith C, et al. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17: 1782–6
56.
Gardner G, Furst DE. Disease-modifying antirheumatic drugs: potential effects in older patients. Drugs Aging 1995; 7: 420–37PubMedCrossRef
57.
Creemers MCW, Franssen MJ, Van De Putte LBA, et al. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995; 22: 1104–7PubMed
58.
Biasi D, Carletto A, Carmaschi P, et al. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000; 19: 114–7PubMedCrossRef
59.
Sampaio-Barros PD, Costallat LTL, Bertolo M, et al. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000; 29: 160–2PubMedCrossRef
60.
Altan L, Bingol U, Karakoc Y, et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001; 30: 255–9PubMedCrossRef
61.
Chepeleva SN, Sigidin YA, Loukina GV. The results of the comparative study of sulphasalazine and methotrexate in ankylosing spondylitis [abstract]. Ann Rheum Dis 2002; 61Suppl. 1: 299–300
62.
Gonzalez-Lopez L, Garcia-Gonzalez A, Vasquez-Del-Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31: 1568–74PubMed
63.
Tett SE, Triggs EJ. Use of methotrexate in older patients: a risk benefit assessment. Drugs Aging 1996; 9: 458–71PubMedCrossRef
64.
Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22: 218–23
65.
Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64Suppl. 2: ii4–7
66.
Fleisch H. Bisphosphonates: preclinical. In: Fleisch III H, editor. Bisphosphonates in bone disease: from the laboratory to the patient. New York: Parthenon Publishing Group, 1997: 32–57
67.
Dunn CJ, Galinet LA, Wu H, et al. Demonstration of novel antiarthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993; 266: 1691–8PubMed
68.
Maksymowych WP. Bisphosphonates: anti-inflammatory properties. Curr Med Chem Antiinflammatory Anti Allergic Agents 2002; 1: 15–28CrossRef
69.
Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46: 785–92PubMedCrossRef
70.
Hasegawa J, Nagashima M, Yamamoto M, et al. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003; 30: 474–9PubMed
71.
Haibel H, Braun J, Maksymowych WP. Bisphosphonates: targeting bone in the treatment of spondyloarthritis. Clin Exp Rheumatol 2002; 20Suppl. 28: S162–S66PubMed
72.
Maksymowych WP. Bisphosphonates for arthritis: a confusing rationale. J Rheumatol 2003; 30: 430–4PubMed
73.
Maksymowych WP, Jhangri GS, Leclercq S, et al. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998; 25: 714–7PubMed
74.
Maksymowych WP, Lambert R, Jhangri GS, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001; 28: 144–55PubMed
75.
Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose response comparison of intravenous pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46: 766–73PubMedCrossRef
76.
Haibel H, Brandt J, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 2003; 42: 1018–20PubMedCrossRef
77.
Toussirot E, Lohse A, Le Huédé G, et al. Treatment of refractory and active spondylarthropathies with pamidronate: an open study [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 395
78.
Toussirot E, Wendling D. Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 2000; 18Suppl. 21: S16–20
79.
Cairns AP, Wright SA, Taggart AJ, et al. An open study of pulse pamidronate therapy in severe ankylosing spondylitis and its effects on biochemical marker of bone turnover. Ann Rheum Dis 2005; 64: 338–9PubMedCrossRef
80.
Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499–505PubMedCrossRef
81.
Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNFα, IL-1β and IFNγ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927–31PubMedCrossRef
82.
Sandborn WJ. Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999; 5: 119–33PubMedCrossRef
83.
Toussirot E, Wendling D. The use of TNF-α blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004; 5: 581–94PubMedCrossRef
84.
Markham A, Lamb HM. Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341–59PubMedCrossRef
85.
Etanercept: soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR001, Enbrel. Drugs R D 1999; 1: 258–61
86.
Machold KP, Smolen JS. Adalimumab: a new TNFα antibody for the treatment of inflammatory joint disease. Expert Opin Biol Ther 2003; 3: 351–60PubMed
87.
Braun J, De Keyser F, Brandt J, et al. New treatment option in spondylarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001; 13: 245–9PubMedCrossRef
88.
Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy. Ann Rheum Dis 2001; 60Suppl. 3: iii58–61PubMed
89.
Van Den Bosch F, Baeten D, Kruithof E, et al. Treatment of active spondylarthropathy with infliximab, the chimeric monoclonal antibody to tumor necrosis factor alpha. Ann Rheum Dis 2001; 60Suppl. 3: iii33–66PubMed
90.
Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52PubMedCrossRef
91.
Van Der Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondylarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428–33PubMedCrossRef
92.
Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001; 28: 1605–14PubMed
93.
Kruithof E, Van Den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody in patients with active spondylarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207–12PubMedCrossRef
94.
Maksymowych W, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959–65PubMed
95.
Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 2002; 41: 1280–5PubMedCrossRef
96.
Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224–33PubMedCrossRef
97.
Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62: 1218–20PubMedCrossRef
98.
Collantes-Estevez E, Munoz-Villanueva MC, Canete-Crespillo JD, et al. Infliximab in refractory spondylarthropathies: a multicentre 38 week open study. Ann Rheum Dis 2003; 62: 1239–40PubMedCrossRef
99.
Marzo-Ortega H, McGonagle D, O’Connor D, et al. Efficacy of etanercept in the treatment of entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112–7PubMedCrossRef
100.
Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patients with severe undifferentiated spondylarthritis with the anti-tumor necrosis factor-α fusion receptor protein etanercept. J Rheumatol 2004; 31: 531–8PubMed
101.
Van Den Bosch F, Kruithof E, Baeten D, et al. Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755–65CrossRef
102.
Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 1187–93PubMedCrossRef
103.
Gorman J, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349–56PubMedCrossRef
104.
Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230–6PubMedCrossRef
105.
Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665–70PubMedCrossRef
106.
Veale DJ, Ritchlin C, Fitzgerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64Suppl. 2: ii26–9PubMedCrossRef
107.
Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90PubMedCrossRef
108.
Mease PJ, Ruderman EM, Ritchlin CT, et al. Etanercept in psoriatic arthritis: sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 99
109.
Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732–4PubMed
110.
Antoni C, Kavanaugh A, Kirkham B, et al. The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT) [abstract]. Arthritis Rheum 2003; 48Suppl. 1: 603
111.
Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor a therapy. Arthritis Rheum 2003; 48: 3013–22PubMedCrossRef
112.
Kroesen S, Widmer AF, Tyndall A, et al. Serious bacterial infections in patients with rheumatoid arthritis under anti TNFα therapy. Rheumatology 2003; 42: 617–21PubMedCrossRef
113.
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med 2001; 345: 1098–104PubMedCrossRef
114.
Salmon-Ceron D, on behalf of the Group RATIO and AFSSAPS. Recommendations for the prevention and management of tuberculosis in patients taking infliximab. Ann Med Interne (Paris) 2002; 153: 429–31
115.
Baeten D, Kruithof E, Van Den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondylarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829–34PubMedCrossRef
116.
Shibata A, Zhao S, Makuch RW, et al. Lymphoma risk in ankylosing spondylitis patients is greater than that observed in the general population [abstract]. Ann Rheum Dis 2004; 63Suppl. 1: 98
117.
Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 20: 807–11
118.
Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004; 63: 1538–43PubMedCrossRef
119.
Cairns A, Taggart A. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002; 71: 101–5PubMed
120.
Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005; 44: 695–6CrossRef
Metadata
Title
Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies
Clinical and Radiological Characteristics and Pharmacological Treatment Options
Authors
Dr Éric Toussirot
Daniel Wendling
Publication date
01-06-2005
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2005
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522060-00001

Other articles of this Issue 6/2005

Drugs & Aging 6/2005 Go to the issue

Review Article

Influenza Vaccination in the Elderly

Review Article

Poststroke Dementia in the Elderly

Leading Article

Adenosine A2A Receptor Antagonists for Parkinson’s Disease

Original Research Article

Clinical Assessment of Effects of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly

Review Article

Reducing the Risk of Stroke in Elderly Patients with Hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits